drugset

drugset / Trial / NCT07507513

The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC

NCT07507513 ↗

Phase 2 Not yet recruiting 288 enrolled Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the efficacy and safety of 627 in patients with UC.

Timeline

Start: 2026-03-31
Primary completion: 2029-02-28
Completion: 2029-12-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	627	Unknown	—	Subcutaneous

Indications